1. Home
  2. AKBA

as 06-13-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Founded: 2007 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 226.4M IPO Year: 2014
Target Price: $4.67 AVG Volume (30 days): 5.0M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.23 EPS Growth: N/A
52 Week Low/High: $0.78 - $2.48 Next Earning Date: 05-09-2024
Revenue: $187,225,000 Revenue Growth: -30.88%
Revenue Growth (this year): -6.34% Revenue Growth (next year): -10.81%

AKBA Daily Stock ML Predictions

Stock Insider Trading Activity of Akebia Therapeutics Inc. (AKBA)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Hadas Nicole R. AKBA SVP, Chief Legal Officer May 13 '24 Sell $1.26 12,016 $15,140.16 651,243 SEC Form 4
Hadas Nicole R. AKBA SVP, Chief Legal Officer Feb 29 '24 Sell $1.58 5,974 $9,438.92 663,259 SEC Form 4
Butler John P. AKBA CEO and President Feb 29 '24 Sell $1.58 46,570 $73,580.60 2,044,580 SEC Form 4
Burke Steven Keith AKBA SVP, Chief Medical Officer Feb 29 '24 Sell $1.58 7,169 $11,327.02 695,840 SEC Form 4
Dahan Michel AKBA SVP, Chief Operating Officer Feb 29 '24 Sell $1.58 8,661 $13,684.38 706,932 SEC Form 4
Burke Steven Keith AKBA SVP, Chief Medical Officer Feb 27 '24 Sell $1.52 8,367 $12,717.84 703,009 SEC Form 4
Dahan Michel AKBA SVP, Chief Operating Officer Feb 27 '24 Sell $1.52 10,744 $16,330.88 715,593 SEC Form 4
Hadas Nicole R. AKBA SVP, Chief Legal Officer Feb 27 '24 Sell $1.52 7,411 $11,264.72 669,233 SEC Form 4
Butler John P. AKBA CEO and President Feb 27 '24 Sell $1.52 37,733 $57,354.16 2,091,150 SEC Form 4
Butler John P. AKBA CEO and President Jan 31 '24 Sell $1.68 46,489 $78,101.52 2,128,883 SEC Form 4
Burke Steven Keith AKBA SVP, Chief Medical Officer Jan 31 '24 Sell $1.68 24,311 $40,842.48 711,376 SEC Form 4
Burke Steven Keith AKBA SVP, Chief Medical Officer Aug 25 '23 Sell $1.15 27,000 $31,050.00 668,840 SEC Form 4

Share on Social Networks: